Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Metacare signs deal, launches 0.2 mg dutasteride hair loss drug in Korea
2+ day, 22+ hour ago (251+ words) The company listed on the Korea Exchange METACARE(118000) said on the 10th that it signed a contract manufacturing deal with Sears Pharmaceutical for a 0.2 mg hair loss treatment containing dutasteride and plans to begin full-scale sales after preparing for production and…...
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata
3+ day, 22+ hour ago (323+ words) The Clinical Trial Vanguard Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata Nektar Therapeutics went quiet on September 8, 2026, and will stay that way until it releases the 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of…...
QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy — TradingView News
4+ day, 8+ hour ago (75+ words) QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy TradingView QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy Positive phase II data for bempikibart in alopecia areata…...
Can We Add Upadacitinib to the Alopecia Areata Arsenal?
2+ week, 3+ day ago (689+ words) Docwire News Upadacitinib Shows Promising Efficacy for Alopecia Areata According to phase 3 data, upadacitinib may represent a potential treatment option for patients with severe alopecia areata. There is currently an unmet need for systemic therapies for alopecia areata—with only…...
Upadacitinib Reached 80 Percent Scalp Coverage in About Half of Severe Alopecia Areata Patients at 24 Weeks
3+ week, 5+ day ago (1037+ words) Two phase 3 trials of the JAK inhibitor upadacitinib produced substantial scalp hair regrowth in roughly half of patients with severe alopecia areata. Published in JAMA Dermatology, the results showed that 55 percent of patients on the higher dose in one trial…...